Opioid Analgesics

Opioid analgesics are drugs that relieve pain by acting at opioid receptors in the nervous system. In anesthesia they are central to providing analgesia and blunting the physiological responses to surgery, and the family ranges from naturally derived alkaloids such as morphine to short-acting synthetic agents such as remifentanil whose properties are tailored to the operating room.

Definition

Opioid analgesics are agents that produce analgesia by binding to opioid receptors — principally the mu receptor — in the central and peripheral nervous systems, mimicking the action of endogenous opioid peptides.

Scope

This topic covers the opioid receptor system and the mechanism of opioid analgesia, the pharmacological classes of opioids (agonists, partial agonists and antagonists), the distinguishing pharmacokinetic features of the agents used perioperatively, and characteristic class effects such as respiratory depression and tolerance. It is a reference and educational account of how opioids act and are classified, not a guide to prescribing or pain management.

Core questions

• How do opioids produce analgesia at the level of opioid receptors?
• How do opioid agonists, partial agonists and antagonists differ pharmacologically?
• What pharmacokinetic features distinguish the opioids used in anesthesia, and what class effects accompany their use?

Key concepts

• Opioid receptors (mu, delta, kappa)
• Endogenous opioid peptides
• Full agonists, partial agonists and antagonists
• Naloxone and opioid reversal
• Respiratory depression
• Tolerance and dependence
• Context-sensitive half-time of opioids

Key theories

Mu-opioid receptor concept

Pasternak and Pan trace how analgesia, and many opioid side effects, are mediated chiefly through the mu-opioid receptor, a G-protein-coupled receptor whose multiple splice variants help explain the variability in response to different mu agonists; this receptor-centred framework underlies the pharmacological classification of opioids.

Mechanisms

Opioids bind to G-protein-coupled opioid receptors, predominantly the mu receptor, on neurons in the brain, spinal cord and periphery. Receptor activation inhibits adenylyl cyclase, opens potassium channels and closes voltage-gated calcium channels, reducing neuronal excitability and neurotransmitter release along pain pathways, which produces analgesia. The same mu-receptor activation accounts for characteristic effects including respiratory depression, sedation, reduced gastrointestinal motility and, with repeated exposure, tolerance and dependence. Antagonists such as naloxone compete at the receptor to reverse these effects. The clinical behaviour of individual opioids is shaped by their pharmacokinetics: remifentanil's esterase metabolism gives an exceptionally brief, infusion-independent offset, while other agents accumulate with prolonged administration.

Clinical relevance

Opioids are a foundational component of balanced anesthesia and perioperative analgesia, and an understanding of their receptor pharmacology and class effects underlies safe use and the recognition of complications such as respiratory depression. This entry is descriptive and educational; it does not provide dosing, prescribing or pain-management instructions, and opioid use carries well-recognised risks that fall outside its scope.

Evidence & guidelines

Opioid receptor pharmacology is grounded in extensive molecular and pharmacological research summarised in reviews such as Pasternak and Pan (2013), while the perioperative behaviour of specific agents is characterised in pharmacokinetic-pharmacodynamic studies such as those underlying Egan (1995) and Shafer and Varvel (1991). Professional-society and public-health guidance on safe opioid use exists but is treatment-oriented and beyond the educational scope of this node.

History

Morphine, isolated from opium in the early nineteenth century, anchored opioid pharmacology long before its mechanism was known. The identification of opioid receptors and endogenous opioid peptides in the 1970s transformed the field, and the subsequent molecular characterisation of receptor subtypes and splice variants, reviewed by Pasternak and Pan (2013), refined understanding of why opioids differ. In parallel, the design of short-acting synthetic opioids such as remifentanil, appraised by Egan (1995), gave anesthesia agents whose offset could be precisely controlled.

Key figures

• Gavril W. Pasternak
• Steven L. Shafer
• Thomas D. Egan

Seminal works

• pasternak-pan-2013
• shafer-varvel-1991

Frequently asked questions

Which opioid receptor is most important for analgesia?

The mu-opioid receptor mediates most of the analgesia produced by clinically used opioids, as well as many of their characteristic effects such as respiratory depression; delta and kappa receptors also contribute to opioid pharmacology.

Why are some opioids used as continuous infusions in anesthesia?

Short-acting synthetic opioids such as remifentanil have very rapid clearance and a brief, infusion-independent offset, which makes them suitable for titration by continuous infusion during surgery; this property is described in their pharmacokinetic characterisation by Egan (1995).